Sonnet BioTherapeutics, an oncology-focused biotech, presents its FHAB technology at EF Hutton Annual Global Conference on May 15, 2024.
Sonnet BioTherapeutics, an oncology-focused biotech firm, will present at the EF Hutton Annual Global Conference on May 15, 2024, in New York. Their proprietary FHAB technology uses human single-chain antibody fragments to target tumor and lymphatic tissues, improving drug safety and efficacy. EF Hutton LLC, the event's host, offers strategic advisory and financing solutions to clients worldwide.
May 06, 2024
4 Articles